NeoMab Fully-Human Antibody Dicovery

: Based on the fully human antibody transgenic mouse NeoMab platform, we have NeoMab-IgG mice (Standard IgG), NeoMab-CLC™ mice (Common Light Chain), and NeoMab-HC™ mice (Heavy Chain Only), which can produce various fully human modules such as IgG, ScFv, Fab, sdAb, and BsAb. This supports the development of a wide range of products for ADCs, AOCs, mono-/bi-/multi-specific antibodies, nanobodies and cell therapies.

TALK WITH OUR EXPERTS

*
*
*
*

COUNTRY/REGION

Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrian Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia Hercegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Is Central African Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Is Costa Rica Cote d'lvoire Croatia Cuba Curaçao Cyprus Czech Denmark Djibouti Dominica Dominican DR Congo East Timor Ecuador Egypt El Salvador Eq.Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas)Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guam Guatemala Guernsey Guinea Guinea Bissau Guyana Haiti Heard Island and McDonald Islands Honduras Hungary Iceland India Indonesia Iran Iraq Ireland Isle Of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kirghizia Kiribati Korea Korea,DPR Kosovo Kuwait Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jm Liechtenstein Lithuania Luxembourg Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Is Rep Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldavia Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Islands Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Barthélemy Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia and Montenegro Seychelles Sierra Leone Singapore Sint Maarten Slovak Slovenia Solomon Is Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka St Kitts-Nevis St.Pierre and Miquelon Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syrian Tajikistan Tanzania Thailand The British Virgin Islands The United States Virgin Islands Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekstan Vanuatu Vatican City State Venezuela Vietnam Wallis and Futuna Islands Western Sahara Yemen Zambia Zimbabwe

*

STATE/PROVINCE

*

How did you hear about us?

Search Engine Social Media Email Colleague Referral Conference Webinar Other

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

I agree to receive other communications from GemPharmatech.

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

I agree to allow GemPharmatech to store and process my personal data.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.